EGFR tyrosine kinase inhibitors (EGFR-TKIs) which are permitted to treat NSCLC patients harboring activating EGFR mutations can block EGFR and lead to great improvement in survival [5]. Here, EGFR is linked to non-small cell lung carcinoma.